ArticleAnnals of surgical oncology2026
Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant nivolumab improves survival after esophageal cancer resection following neoadjuvant therapy; however, postoperative recurrence remains a major clinical challenge. This study investigated postoperative recurrence and identified the prognostic factors in patients receiving adjuvant nivolumab after esophagectomy. PATIENTS AND
methodsThis single-center retrospective study included 82 consecutive patients with locally advanced esophageal cancer who received adjuvant nivolumab after esophagectomy following preoperative therapy. Cox proportional hazards regression models were used to identify independent risk factors for postoperative recurrence.
resultsThe cohort predominantly consisted of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy and minimally invasive esophagectomy, most of whom had pathological lymph node metastases. During a median follow-up of 30.6 months, 44 patients (54%) developed recurrence, and 30 (37%) developed recurrence during adjuvant nivolumab therapy. The median recurrence-free survival (RFS) was 30.8 months, with a 2-year RFS rate of 50.7% and an overall survival rate of 81.7%. Multivariable analysis identified poor response to preoperative therapy, ypN3 disease, pretreatment prognostic nutritional index (PNI) < 44, and absence of immune-related adverse events (irAEs) as independent risk factors for postoperative recurrence. Subgroup analyses demonstrated markedly lower 2-year RFS rates in patients with stable disease compared with those with complete response or partial response (27.3% vs. 61.8%), ypN3 compared with ypN1-2 (19.4% vs. 58.5%), PNI < 44 compared with ≥ 44 (24.2% vs. 57.8%), and non-irAEs compared with any irAEs (47.5% vs. 55.9%).
conclusionsTumor-related characteristics and host-related immune and nutritional factors were independently associated with the risk of recurrence after adjuvant nivolumab therapy.
Indexed as
Identifiers
41979848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.